Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 1705 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Lanxess Swings Into Profit In Q4

EBITDA pre exceptionals in the fourth quarter of 2009 was EUR144m, slightly high compared to EUR87m in the fourth quarter of 2008, which was dominated by the effects

Antisoma Starts Phase IIb AS1411 Trial

AS1411 belongs to a new type of drug called aptamers. These drugs are short pieces of DNA or RNA that fold into three-dimensional structures capable of targeting particular

Angel Biotechnology Inks GMP Contracts With ReNeuron

The new contracts support ReNeuron’s clinical trial activities by the manufacture of additional clinical-grade material (drug substance lots) and the provision of manufacturing process validation services. Gordon Sherriff,